Real-world Analysis of Acamprosate Use in Patients with Cirrhosis and Alcohol-associated Hepatitis

Overview

Journal BMJ Open Gastroenterol

Date 2025 Jan 11

PMID 39797662

Authors

Christopher Oldroyd

Jonathan Wood

Michael Allison

Affiliations

Soon will be listed here.

Abstract

Objective: Preventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate prescription in patients with advanced liver disease on abstinence rates and clinical outcomes.

Methods: This was a retrospective case-control study. We reviewed data on all patients admitted to a large tertiary centre in the UK with alcohol-related cirrhosis and/or alcohol-associated hepatitis. We used propensity risk score matching to match patients prescribed acamprosate to controls. The primary outcome was repeat hospitalisation.

Results: There were 451 patients who met the inclusion criteria of whom 55 patients were started on acamprosate during their admission. Before matching there were significant differences between the cohorts. Patients who received acamprosate were younger (median age 51 vs 57, p<0.005), more likely to have a purely alcohol-related admission (53% vs 24%, p<0.001), and more likely to suffer from a comorbid psychiatric diagnosis (42% vs 20%, p<0.001). On average patients who were started on acamprosate consumed more alcohol (median 155 units/week vs 80 units/week, p<0.001), were less likely to have a partner (35% vs 54%, p 0.006) and more likely to be unemployed (67% vs 44%, p<0.001). After matching for factors with significant differences between groups, we generated a cohort of 53 patients prescribed acamprosate and 53 matched controls. At 1 year there was a significantly higher rate of readmission (85% vs 57%, p<0.001) in the acamprosate group. There were no statistically significant differences in abstinence rates or mortality at 1 year.

Conclusion: Acamprosate prescription was associated with higher rates of readmission in patients with cirrhosis and/or alcohol-associated hepatitis. This may reflect a greater severity of AUD in those patients or might indicate the limited ability of acamprosate to alter the disease course in this population.

References

Thursz M, Richardson P, Allison M, Austin A, Bowers M, Day C . Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015; 372(17):1619-28. DOI: 10.1056/NEJMoa1412278. View

Bjornsson E, Hauksson K, Sigurdardottir R, Arnardottir M, Agustsson A, Lund S . Abstinence from alcohol and alcohol rehabilitation therapy in alcoholic liver disease: a population-based study. Scand J Gastroenterol. 2020; 55(4):472-478. DOI: 10.1080/00365521.2020.1743751. View

Hofer B, Simbrunner B, Hartl L, Jachs M, Bauer D, Balcar L . Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis. Clin Gastroenterol Hepatol. 2022; 21(9):2308-2317.e7. DOI: 10.1016/j.cgh.2022.11.033. View

Tolomeo S, Baldacchino A . Adherence to Prescribed Acamprosate in Alcohol Dependence and 1-Year Morbidities and Mortality: Utilizing a Data Linkage Methodology. J Clin Med. 2021; 10(10). PMC: 8153116. DOI: 10.3390/jcm10102102. View

Heikkinen M, Taipale H, Tanskanen A, Mittendorfer-Rutz E, Lahteenvuo M, Tiihonen J . Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients. Addiction. 2021; 116(8):1990-1998. PMC: 8359433. DOI: 10.1111/add.15384. View

Devarbhavi H, Asrani S, Arab J, Nartey Y, Pose E, Kamath P . Global burden of liver disease: 2023 update. J Hepatol. 2023; 79(2):516-537. DOI: 10.1016/j.jhep.2023.03.017. View

Rogal S, Youk A, Zhang H, Gellad W, Fine M, Good C . Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. Hepatology. 2019; 71(6):2080-2092. PMC: 8032461. DOI: 10.1002/hep.31042. View

Garcia-Saenz-de-Sicilia M, Duvoor C, Altamirano J, Chavez-Araujo R, Prado V, de Lourdes Candolo-Martinelli A . A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis. Am J Gastroenterol. 2016; 112(2):306-315. DOI: 10.1038/ajg.2016.539. View

Oldroyd C, Greenham O, Martin G, Allison M, Notley C . Systematic review: Interventions for alcohol use disorder in patients with cirrhosis or alcohol-associated hepatitis. Aliment Pharmacol Ther. 2023; 58(8):763-773. DOI: 10.1111/apt.17665. View

10.

Arab J, Izzy M, Leggio L, Bataller R, Shah V . Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation. Nat Rev Gastroenterol Hepatol. 2021; 19(1):45-59. PMC: 8559139. DOI: 10.1038/s41575-021-00527-0. View

11.

Potts J, Goubet S, Heneghan M, Verma S . Determinants of long-term outcome in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2013; 38(6):584-95. DOI: 10.1111/apt.12427. View

12.

Kalk N, Lingford-Hughes A . The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2013; 77(2):315-23. PMC: 4014018. DOI: 10.1111/bcp.12070. View

13.

Lim W, Tay P, Ng C, Tan D, Ong C, Koh J . Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. Aliment Pharmacol Ther. 2024; 59(6):730-741. PMC: 11371415. DOI: 10.1111/apt.17888. View

14.

Tyson L, Cheng A, Kelleher C, Strathie K, Lovendoski J, Habtemariam Z . Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. Eur J Gastroenterol Hepatol. 2022; 34(5):567-575. DOI: 10.1097/MEG.0000000000002304. View

15.

Kalaitzakis E, Wallskog J, Bjornsson E . Abstinence in patients with alcoholic liver cirrhosis: A follow-up study. Hepatol Res. 2008; 38(9):869-76. DOI: 10.1111/j.1872-034X.2008.00353.x. View

16.

Jonas D, Amick H, Feltner C, Bobashev G, Thomas K, Wines R . Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014; 311(18):1889-900. DOI: 10.1001/jama.2014.3628. View

17.

Vannier A, Shay J, Fomin V, Patel S, Schaefer E, Goodman R . Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder. JAMA Netw Open. 2022; 5(5):e2213014. PMC: 9123494. DOI: 10.1001/jamanetworkopen.2022.13014. View

18.

Reid S, Teesson M, Sannibale C, Matsuda M, Haber P . The efficacy of compliance therapy in pharmacotherapy for alcohol dependence: a randomized controlled trial. J Stud Alcohol. 2006; 66(6):833-41. DOI: 10.15288/jsa.2005.66.833. View

19.

Mellinger J, Winder G . Alcohol Use Disorders in Alcoholic Liver Disease. Clin Liver Dis. 2018; 23(1):55-69. DOI: 10.1016/j.cld.2018.09.004. View